AR108333A1 - Tratamiento de la dermatitis atópica canina - Google Patents
Tratamiento de la dermatitis atópica caninaInfo
- Publication number
- AR108333A1 AR108333A1 ARP170101065A ARP170101065A AR108333A1 AR 108333 A1 AR108333 A1 AR 108333A1 AR P170101065 A ARP170101065 A AR P170101065A AR P170101065 A ARP170101065 A AR P170101065A AR 108333 A1 AR108333 A1 AR 108333A1
- Authority
- AR
- Argentina
- Prior art keywords
- antigen
- seq
- protein
- cil
- sequence
- Prior art date
Links
- 206010012438 Dermatitis atopic Diseases 0.000 title abstract 2
- 201000008937 atopic dermatitis Diseases 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 7
- 102000036639 antigens Human genes 0.000 abstract 7
- 108091007433 antigens Proteins 0.000 abstract 7
- 108090000623 proteins and genes Proteins 0.000 abstract 5
- 102000004169 proteins and genes Human genes 0.000 abstract 5
- 241000282465 Canis Species 0.000 abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
- 241000824799 Canis lupus dingo Species 0.000 abstract 2
- 102100021596 Interleukin-31 Human genes 0.000 abstract 2
- 101710181613 Interleukin-31 Proteins 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 239000007771 core particle Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/00023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/14011—Bromoviridae
- C12N2770/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/14011—Bromoviridae
- C12N2770/14023—Virus like particles [VLP]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Una composición para el uso en un método para prevenir o tratar la dermatitis atópica canina (CAD) de un cánido, preferentemente de un perro doméstico, donde se administra una cantidad efectiva de dicha composición a dicho cánido, preferentemente a dicho perro doméstico, y donde dicha composición comprende: (a) una partícula de núcleo con por lo menos un primer sitio de unión; y (b) por lo menos un antígeno de interleuquina-31 canina (antígeno cIL-31) con por lo menos un segundo sitio de unión, donde dicho antígeno cIL-31 comprende o preferentemente consiste en una proteína con la secuencia amino seleccionada de SEQ ID Nº 22 o una proteína con una secuencia de aminoácidos de por lo menos 90%, preferentemente de por lo menos 92%, más preferentemente de por lo menos 95%, y de nuevo más preferentemente de por lo menos 98% de identidad de secuencia de aminoácidos con SEQ ID Nº 22; donde (a) y (b) están enlazados a través de dicho por lo menos un primer y dicho por lo menos un segundo sitios de unión a través de por lo menos un enlace covalente no peptídico. Reivindicación 13: Una composición que comprende: (a) una partícula de tipo viral (VLP) con por lo menos un primer sitio de unión; (b) por lo menos un antígeno de interleuquina-31 canina (antígeno cIL-31) con por lo menos un segundo sitio de unión, donde dicho antígeno cIL-31 comprende o preferentemente consiste en una proteína con la secuencia amino seleccionada de SEQ ID Nº 22 o una proteína con una secuencia de aminoácidos de por lo menos 90%, preferentemente de por lo menos 92%, más preferentemente de por lo menos 95%, y de nuevo más preferentemente de por lo menos 98% de identidad de secuencia de aminoácidos con SEQ ID Nº 22, nuevamente más preferentemente, dicho antígeno comprende, o preferentemente consiste en una proteína con la secuencia amino de la SEQ ID Nº 22; donde (a) y (b) están enlazados a través de dicho por lo menos un primer y dicho por lo menos un segundo sitios de unión a través de por lo menos un enlace covalente no peptídico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16167264 | 2016-04-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR108333A1 true AR108333A1 (es) | 2018-08-08 |
Family
ID=56024099
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170101065A AR108333A1 (es) | 2016-04-27 | 2017-04-26 | Tratamiento de la dermatitis atópica canina |
Country Status (17)
Country | Link |
---|---|
US (1) | US10946078B2 (es) |
EP (1) | EP3448422A1 (es) |
JP (2) | JP7039561B2 (es) |
KR (2) | KR102469478B1 (es) |
CN (2) | CN109562156B (es) |
AR (1) | AR108333A1 (es) |
AU (2) | AU2017256727B2 (es) |
BR (1) | BR112018071965A2 (es) |
CA (1) | CA3019653A1 (es) |
CL (1) | CL2018002960A1 (es) |
CO (1) | CO2018011087A2 (es) |
EA (1) | EA201892003A1 (es) |
MX (1) | MX2022009171A (es) |
NZ (1) | NZ747512A (es) |
UA (1) | UA126852C2 (es) |
WO (1) | WO2017186813A1 (es) |
ZA (1) | ZA201806503B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019118512A2 (en) * | 2017-12-11 | 2019-06-20 | Ubi Ip Holdings | Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis |
BR112020017715A2 (pt) | 2018-03-16 | 2020-12-29 | Zoetis Services Llc | Vacinas de peptídeo contra interleucina-31 |
CN112020511A (zh) | 2018-03-16 | 2020-12-01 | 硕腾服务有限责任公司 | 用于兽医用途的白介素-31单克隆抗体 |
MX2021007285A (es) * | 2018-12-20 | 2021-09-23 | Saiba AG | Particulas similares a virus del cmv modificadas por fusion. |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040024004A1 (en) | 2001-05-04 | 2004-02-05 | Sherman Barry M. | Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists |
AU2002339224B2 (en) | 2001-09-14 | 2008-10-09 | Kuros Us Llc | Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
CN101023103A (zh) * | 2004-09-21 | 2007-08-22 | 赛托斯生物技术公司 | 包含ap205外壳蛋白和抗原性多肽的融合蛋白的病毒样颗粒 |
EP1791870A1 (en) | 2004-09-21 | 2007-06-06 | Cytos Biotechnology AG | Virus-like particles comprising a fusion protein of the coat protein of ap205 and an antigenic polypeptide |
MX2007009718A (es) | 2005-02-14 | 2007-09-26 | Zymogenetics Inc | Metodos para tratar trastornos cutaneos utilizando un antagonista il-31ra. |
US20070184068A1 (en) | 2005-12-14 | 2007-08-09 | Cytos Biotechnology Ag | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
WO2008112674A1 (en) | 2007-03-12 | 2008-09-18 | Irm Llc | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity |
US8465756B2 (en) * | 2009-08-12 | 2013-06-18 | National Health Research Institutes | Immunogenic peptides of tumor associated antigen L6 and uses thereof in cancer therapy |
US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
JP2016509671A (ja) | 2013-01-04 | 2016-03-31 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | オピオイド受容体のポジティブアロステリックモジュレーターおよびサイレントアロステリックモジュレーター |
WO2015042596A1 (en) | 2013-09-23 | 2015-03-26 | Kindred Biosciences, Inc | Treatment of atopic dermatitis in non-human animals |
MA40824A (fr) * | 2014-10-22 | 2017-08-29 | Saiba Gmbh | Particules de cmv de type virus modifié |
-
2017
- 2017-04-26 CN CN201780025651.8A patent/CN109562156B/zh active Active
- 2017-04-26 AR ARP170101065A patent/AR108333A1/es unknown
- 2017-04-26 US US16/097,156 patent/US10946078B2/en active Active
- 2017-04-26 JP JP2019508291A patent/JP7039561B2/ja active Active
- 2017-04-26 WO PCT/EP2017/059977 patent/WO2017186813A1/en active Application Filing
- 2017-04-26 KR KR1020187031190A patent/KR102469478B1/ko active IP Right Grant
- 2017-04-26 BR BR112018071965A patent/BR112018071965A2/pt unknown
- 2017-04-26 UA UAA201809978A patent/UA126852C2/uk unknown
- 2017-04-26 KR KR1020227040222A patent/KR20220162800A/ko not_active Application Discontinuation
- 2017-04-26 AU AU2017256727A patent/AU2017256727B2/en active Active
- 2017-04-26 EP EP17723294.9A patent/EP3448422A1/en active Pending
- 2017-04-26 NZ NZ747512A patent/NZ747512A/en unknown
- 2017-04-26 CA CA3019653A patent/CA3019653A1/en active Pending
- 2017-04-26 EA EA201892003A patent/EA201892003A1/ru unknown
- 2017-04-26 CN CN202310179224.2A patent/CN116688110A/zh active Pending
-
2018
- 2018-10-01 ZA ZA2018/06503A patent/ZA201806503B/en unknown
- 2018-10-16 CO CONC2018/0011087A patent/CO2018011087A2/es unknown
- 2018-10-17 CL CL2018002960A patent/CL2018002960A1/es unknown
- 2018-10-24 MX MX2022009171A patent/MX2022009171A/es unknown
-
2022
- 2022-03-09 JP JP2022036245A patent/JP7273214B2/ja active Active
- 2022-12-19 AU AU2022291431A patent/AU2022291431A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CO2018011087A2 (es) | 2019-02-08 |
JP7039561B2 (ja) | 2022-03-22 |
CA3019653A1 (en) | 2017-11-02 |
KR20190003948A (ko) | 2019-01-10 |
US20190209668A1 (en) | 2019-07-11 |
EP3448422A1 (en) | 2019-03-06 |
KR102469478B1 (ko) | 2022-11-23 |
MX2022009171A (es) | 2022-08-17 |
BR112018071965A2 (pt) | 2019-03-06 |
KR20220162800A (ko) | 2022-12-08 |
CN116688110A (zh) | 2023-09-05 |
CL2018002960A1 (es) | 2019-01-25 |
AU2017256727A1 (en) | 2018-11-15 |
US10946078B2 (en) | 2021-03-16 |
JP2022078254A (ja) | 2022-05-24 |
AU2022291431A1 (en) | 2023-03-30 |
UA126852C2 (uk) | 2023-02-15 |
ZA201806503B (en) | 2019-07-31 |
WO2017186813A1 (en) | 2017-11-02 |
CN109562156A (zh) | 2019-04-02 |
NZ747512A (en) | 2023-05-26 |
AU2017256727B2 (en) | 2022-09-29 |
JP2019515957A (ja) | 2019-06-13 |
JP7273214B2 (ja) | 2023-05-12 |
EA201892003A1 (ru) | 2019-05-31 |
CN109562156B (zh) | 2023-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR108333A1 (es) | Tratamiento de la dermatitis atópica canina | |
AR107521A1 (es) | Constructos de anticuerpo biespecíficos para bcma y cd3 que se ligan a células t | |
PE20191463A1 (es) | Anticuerpos biespecificos de union especifica pd1 y lag3 | |
AR109680A1 (es) | Proteínas recombinantes y sus usos | |
BR112017020952A2 (pt) | método de tratamento de câncer, composição e uso da composição | |
BR112019011277A2 (pt) | polinucleotídeo, sistema de expressão recombinante, vetor, polipeptídeo, célula recombinante, polipeptídeo de receptor imune sintético isolado ou heterodímero de polipeptídeo, célula efetora imune ou célula-tronco, população de células imunes ou efetoras, métodos de fabricação de uma célula efetora imune que expressa sir, de geração de uma população de células modificadas por rna, de fornecimento de imunidade antidoença e de tratamento ou prevenção de uma doença, composição, uso ou método, kit, e, sequência de aminoácidos. | |
PE20170771A1 (es) | Composiciones y metodos de uso para tratar trastornos metabolicos | |
UA111166C2 (uk) | Композиція проти salmonella typhimurium та спосіб обробки корму для тварин | |
CL2012002095A1 (es) | Polipéptido de unión biparatópico que comprende un primer dominio variable individual de inmunoglobulina (ig) que se une específicamente a un primer epítopo del péptido ß-amiloide (ßa) y un segundo dominio variable de ig que se une específicamente a un segundo epítopo del ßa, donde dichos epítopos del ßa no son idénticos; ácido nucleico que lo codifica; vector; célula hospedera; composición farmacéutica; método de preparación; y su uso en el tratamiento y/o prevención de depósitos del ßa | |
AR095596A1 (es) | Moléculas de unión de cadena única comprendiendo n-terminal abp | |
AR091024A1 (es) | Anticuerpos capaces de unirse al factor xi de coagulacion y/o a su forma activada, factor xia, y sus usos | |
CL2019003404A1 (es) | Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico.(divisional solicitud 201702407) | |
JP2014000092A5 (es) | ||
PE20142114A1 (es) | Polipeptidos de receptores de activina variantes, solos o en combinacion con quimioterapia, y sus usos | |
PE20140190A1 (es) | Moduladores de proteinas notum y metodos de uso | |
CO2018002203A2 (es) | Tratamiento de la hipersensibilidad a picaduras de insectos | |
AR095611A1 (es) | Anticuerpos que se unen al receptor del polipéptido activador de la adenilato ciclasa pituitaria humana tipo i (hpac1) | |
BR112017001339A2 (pt) | método, pasta de cimento e sistema | |
RS54057B1 (en) | ANTIKANCERSKI PROTEIN FUNCTIONS | |
AR093778A1 (es) | PROTEINAS LIGANTES DE ANTIGENO ANTI-HER3/HER4 DE UNION A LA HORQUILLA b DE HER3 Y A LA HORQUILLA b DE HER4 | |
AR110093A1 (es) | D-psicosa 3-epimerasa y método para preparar d-psicosa utilizando la misma | |
BR112017005744A2 (pt) | sistema de genética reversa para vírus pichinde e método de uso | |
CO2017011431A2 (es) | Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina | |
EA201691004A1 (ru) | Последовательность модифицированного эндолизина kz144 | |
CL2015002989A1 (es) | Mezcla de polímeros para floculación |